Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
The Pharma Data
OCTOBER 27, 2021
Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.
Let's personalize your content